Journal article

Assessment of F-18-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

Matthias Brendel, Henryk Barthel, Thilo van Eimeren, Ken Marek, Leonie Beyer, Mengmeng Song, Carla Palleis, Mona Gehmeyr, Urban Fietzek, Gesine Respondek, Julia Sauerbeck, Alexander Nitschmann, Christian Zach, Jochen Hammes, Michael T Barbe, Oezguer Onur, Frank Jessen, Dorothee Saur, Matthias L Schroeter, Jost-Julian Rumpf Show all

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2020


Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers that support diagnosis. Objective: To investigate the potential of the novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed PSP. Design, Setting, and Participants: In this cross-sectional study, participants underwent dynamic 18F-PI-2620 positron emission tomography (PET) from 0 to 60 minutes after injection at 5 different centers (3 in Germany, 1 in the US, and 1 in Australia). Patients with PSP (incl..

View full abstract

University of Melbourne Researchers